KNG1 and atherosclerosis: In agreement with a bradykinin-independent function of the B2 bradykinin receptor in atherosclerosis, treatment of ApoE–/– mice with the B2 bradykinin receptor-specific antagonist, HOE140, did not alter atherosclerosis progression (13).